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http://dx.doi.org/10.1016/j.ccr.2013.08.018SUMMARYAberrant expression of embryonic epithelial-mesenchymal transition-inducing transcription factors (EMT-
TFs) in epithelial cells triggers EMT, neoplastic transformation, stemness, and metastatic dissemination.
We found that regulation and functions of EMT-TFs are different in malignant melanoma. SNAIL2 and
ZEB2 transcription factors are expressed in normal melanocytes and behave as tumor-suppressor proteins
by activating anMITF-dependentmelanocyte differentiation program. In response to NRAS/BRAF activation,
EMT-TF network undergoes a profound reorganization in favor of TWIST1 and ZEB1. This reversible switch
cooperates with BRAF in promoting dedifferentiation and neoplastic transformation of melanocytes. We
detected EMT-TF reprogramming in late-stagemelanoma in associationwith enhanced phospho-ERK levels.
This switch results in E-cadherin loss, enhanced invasion, and constitutes an independent factor of poor
prognosis in melanoma patients.INTRODUCTION
Epithelial-mesenchymal transition (EMT) is a reversible embry-
onic genetic program, which produces motile cells from
polarized epithelia. EMT is driven by a network of embryonicSignificance
In epithelial cells, the aberrant reactivation of transcription fact
known to facilitate both neoplastic transformation and tumor c
magenesis SNAIL2 and ZEB2 transcription factors drive amela
sive proteins, whereas ZEB1 and TWIST1 repress differentiatio
from tumor-suppressive to oncogenic EMT-TF expression pa
activatingmolecular pathways that are critical tomelanoma init
and function of embryonic EMT-TFs in malignant melanoma an
insight into cooperation between classical oncogenes and
progression.
466 Cancer Cell 24, 466–480, October 14, 2013 ª2013 Elsevier Inc.EMT-inducing transcription factors (EMT-TFs) represented by
several protein families, such as SNAIL, TWIST, or ZEB. The
aberrant expression of EMT-TFs is frequently observed in
various cancer types, particularly in carcinomas, and is often
associated with poor prognosis and high risk of metastasisors inducing epithelial-mesenchymal transition (EMT-TFs) is
ell dissemination. We have now shown that during melano-
nocytic differentiation program and behave as oncosuppres-
n and possess oncogenic properties. The reversible switch
ttern is driven by mitogen-activated protein kinase (MAPK)-
iation and progression. Our data demonstrate that regulation
d epithelial tumors are dissimilar. Overall, these data provide
embryonic genetic programs during tumor initiation and
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EMT-TFs and Melanomagenesis(Thiery et al., 2009; Peinado et al., 2007). Their oncogenic poten-
tial relies on their ability to promote escape from oncogene-
induced fail-safe programs by interfering with critical tumor
suppressor pathways including p53, RB, and PP2A (Maestro
et al., 1999; Valsesia-Wittmann et al., 2004; Ansieau et al., 2008;
Morel et al., 2012). At later stages of carcinoma development,
the EMT-resembling processes initiated by EMT-TFs contribute
to accelerated tumor progression and metastases (Peinado
et al., 2007). Importantly, EMT results in the acquisition of stem
cell-like properties including slow proliferation and self-renewal
potential (Vega et al., 2004; Mejlvang et al., 2007; Mani et al.,
2008; Morel et al., 2008). The flexible and transient nature of
EMT pathways determines reversible switches between prolifer-
ative and invasive phenotypes and manifests plasticity of tumor
cells in aggressive carcinomas (Tsai et al., 2012; Ocan˜a et al.,
2012; Brabletz, 2012a, 2012b). Tumor cell plasticity depends on
microenvironmental cues and is responsible for drug resistance
and for driving epithelial tumorigenesis through balancing tumor
growth and spread (Iliopoulos et al., 2011; Nieto andCano, 2012).
A high degree of phenotypic plasticity is a hallmark of malig-
nant melanoma (MM), a most aggressive skin cancer originating
from neural crest-derived melanocytes. In MM, phenotypic plas-
ticity is controlled by a master regulator of melanocyte develop-
ment, the microphthalmia-associated transcription factor (MITF)
(Cheli et al., 2010; Bell and Levy, 2011). In contrast to themajority
of epithelial tissues, normal melanocytes express some EMT-
TFs, and this was considered as an intrinsic factor predisposing
MM to high metastatic propensity (Gupta et al., 2005). As mela-
nocytes do not belong to epithelial lineage, the term ‘‘EMT’’
cannot be formally attributed to the progression of MM. How-
ever, differentiated melanocytes do express E-cadherin, which
is required for their contacts with keratinocytes in the basal layer
of the epidermis. These communications maintain differentiation
state of melanocytes and suppress their proliferation. Loss of
E-cadherin that represents a hallmark of EMT in epithelial tumors
is also evident in late-stage MM, especially in nodal metastases
(Miller and Mihm, 2006; Alexaki et al., 2010).
It is well established that MM is driven by the activation of
MEK-ERK signaling, most frequently through the mutations in
BRAF or NRAS oncogenes. However, a molecular link between
this pathway, cell plasticity, and EMT-TF network in MM cells
remains not studied. Here, we analyze regulation and function
of EMT-TFs in MM with the aim to assess a role for EMT-resem-
bling processes in melanomagenesis.
RESULTS
EMT-TF Switching in Human Melanoma Samples
Expression of some EMT-inducers in melanomas has been
reported previously (Hoek et al., 2004; Ansieau et al., 2008;
Shirley et al., 2012; Mikesh et al., 2010). However, no compre-
hensive study on the EMT-TF network in MM has yet been per-
formed. We therefore analyzed the expression of SNAIL1,
SNAIL2, TWIST1, ZEB1, and ZEB2 proteins in a series of human
tissues representing melanoma progression, including normal
epidermis, common acquired nevi, primary MM, and meta-
stases. In addition, we evaluated the IHC staining of a selected
cohort of primary MM to investigate the clinical significance of
the EMT-TF network. In a recent report, SNAIL1 has been shownCto be absent in 96% of MM samples (Mikesh et al., 2010). In
agreement with these data, 24MM samples including 12 primary
tumors and matched metastases were SNAIL1-negative; there-
fore we excluded SNAIL1 from further analyses.
Remarkably, ZEB2andSNAIL2 showed strongnuclear expres-
sion in normal epidermal melanocytes, in which ZEB1 and
TWIST1 were absent (Figure S1A available online). The analyses
of themelanomaprogression series showed twoopposing trends
within andbetween lesions.Within lesions, a distinct gradientwas
observed, where ZEB2 and SNAIL2 were strongly expressed in
superficial sites with weaker or absent nuclear staining in the
deep sites of nevi (n = 26) and primary MMs (n = 151) (Wilcoxon
matched pairs test, p < 0.0001). ZEB1 and TWIST1 showed the
opposite gradient with stronger focal staining at the deep sites
of primary MMs compared to superficial sites in these lesions
(p < 0.0001) (Figures 1A and S1). In cortical and medullar parts
of metastases, we detected similar gradients of immunopositivity
for EMT-TFs (n = 51, p < 0.0001) (Figures S1B and S1C).
Likewise, a reciprocal pattern of IHC staining was observed
between lesions with melanoma progression. We observed a
progressive loss of ZEB2 immunopositivity in superficial and
deep sites of primary MM and medullar sites of independent
metastases (n = 101, p < 0.001 and n = 51, p < 0.001 respec-
tively, Jonckheere-Terpstra trend test; Figures 1A and S1B–
S1D) and loss of ZEB2 and SNAIL2 staining in matchedmetasta-
tic lesions (n = 31, p < 0.01 and n = 28, p < 0.01 respectively,
Page’s L trend) (Figure S1E). ZEB1 showed increased immuno-
positivity with tumor progression. H-score values showed a
significant increasing trend from primary MM to medullar sites
of independent (n = 101, p < 0.0001 superficial, n = 101, p <
0.0001 deep Jonckheere-Terpstra trend test) or matched meta-
static lesions (n = 31, p < 0.01, Page’s L trend) (Figures S1D and
S1E; Table S1). For TWIST1, the superficial staining showed a
significant increasing trend with progression (n = 101, p <
0.014, Jonckheere-Terpstra trend test) (Table S1).
Overall, we characterized a trend of transition from ZEB2high/
SNAIL2high/ZEB1low/TWIST1low toward a ZEB2low/SNAIL2low/
ZEB1high/TWIST1high expression pattern. This transition was
evident at deeper sites of the lesions and correlated with the level
of malignancy.
These findings prompted us to perform survival analyses for all
primary melanomas with follow-up data (the Kaplan-Meier
method; n = 98) for superficial and deep staining of ZEB1,
ZEB2, and TWIST1. Significant shorter metastasis-free survival
was observed for Breslow depth, high ZEB1, and low ZEB2
levels at deep sites and high TWIST1 at superficial sites (Fig-
ure 1B; Table S1). Two-step cluster analysis using IHC H-scores
of these EMT-TFs identified three distinct natural groups of
expression representing a switch in EMT-TFs from ZEB2/
SNAIL2 to ZEB1/TWIST1 with significant differences in clinical
outcome (Figure 1B; Table S1). In a multivariate analysis, both
superficial and deep staining of ZEB1 and TWIST1 combined
with Breslow thickness were all significant independent predic-
tors of time to metastasis. Loss of deep ZEB2 staining showed
decreased metastasis-free survival but not independent of
tumor depth (Table S1). Together, these data demonstrate that
a switch from ZEB2/SNAIL2 to ZEB1/TWIST1 expression con-
stitutes a major risk factor for poor outcome in MM when con-
trolling for other clinico-pathological variables.ancer Cell 24, 466–480, October 14, 2013 ª2013 Elsevier Inc. 467
Figure 1. Opposing Trends of EMT-TF Expression in Melanocytic Lesions
(A) Examples of representative IHC analyses of EMT-TF expression at superficial and deep sites of primary melanoma samples. The images exemplify opposing
gradients of ZEB2 and SNAIL2 versus ZEB1 and TWIST1 expression within the lesions. Tumor borders are indicated with dashed yellow lines.
(B) Metastasis-free survival of patients with MM according to EMT-TF expression. Note significantly shorter metastasis-free survival of patients with ZEB2-
negative tumors expressing ZEB1 and TWIST1.
See also Figure S1 and Table S1.
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Perturbs the Expression of EMT-TFs
Perturbed expression of EMT-TFs in MM samples prompted us
to explore a potential interrelationship between this reprogram-
ming and the NRAS or BRAF melanoma-driving pathways. To
activate this pathway in melanocytes, we transduced immortal-
ized, but nontransformed murine C57 BL/6J-derived melan-a
cells with the tamoxifen-inducible version of a dominant-active
truncated variant of BRAF (DBRAF-ER). In parallel, human
primary melanocytes (NHEM) were infected with a vector ex-
pressing a constitutively active mutant BRAFV600E. Consistent
with the results of the IHC analyses of normal skin (Figure S1A),
nontransformedmelanocytes in culture were positive for SNAIL2
and ZEB2, but negative for ZEB1 and TWIST1 (Figure 2A).
Activation of the BRAF pathway converted the expression of
EMT-TFs to a ZEB2low/SNAIL2low/ZEB1high/TWIST1high pattern
consistent with the EMT-TF reprogramming observed by the
analyses of deeper lesions of more malignant melanoma
samples (Figure 2A).
Next, we addressed whether the constitutive BRAF or NRAS
signaling is required to maintain EMT-TF expression pattern in
melanoma cell lines. In line with the data obtained in NHEM468 Cancer Cell 24, 466–480, October 14, 2013 ª2013 Elsevier Inc.andmelan-a cells, MEK inhibition upregulated ZEB2 and SNAIL2
and downregulated ZEB1 and TWIST1 in melanoma cell lines
with mutations in BRAF or NRAS (Figure 2B). The effect of a
specific BRAF inhibitor was identical with that of MEK inhibitors
inBRAFmutant cells, such as A375P, but not in anNRASmutant
IPC-298 cell line, likely due to the activation of the NRAS-CRAF
pathway (Heidorn et al., 2010). Collectively, these data demon-
strated that in both murine and human species, BRAF activation
drives a rapid and reversible switch in EMT-TF expression, and
the activity of this pathway is necessary and sufficient to
maintain MM-specific pattern of EMT-TF expression.
Although the absolute majority of melanocytic lesions
including nonmalignant nevi contain MAPK-activating muta-
tions, the strength of the signaling is different and modulated
by various negative feedback and bypass mechanisms
(Wajapeyee et al., 2008; Nikolaev et al., 2012; Li et al., 2012;
Martin et al., 2012). Consequently, variable levels of phospho-
ERK immunopositivity were reported in the lesions, with higher
expression in late-stagemelanoma and low or lack of expression
in nevi (Saldanha et al., 2004; Uribe et al., 2006; Venesio et al.,
2008; Yazdi et al., 2010). To validate the results obtained
in vitro, we analyzed phospho-ERK expression in a subset of
Figure 2. RAS-BRAF Pathway Induces a Reversible Switch in EMT-TF Expression
(A) Activation of BRAF pathway in nontransformed melanocytes upregulates ZEB1, TWIST1, and FRA1, but downregulates ZEB2 and SNAIL2. Expression of an
activated form of BRAF in melan-a cells was induced by tamoxifen (4-OHT) treatment of melan-a/DBRAF-ER cells for 72 hr. NHEM cells were infected with a
lentiviral vector harboring BRAFV600E point mutation. Protein expression was analyzed by immunoblotting.
(B) Chemical inhibitors of BRAF and MEK downregulate ZEB1, TWIST1, and FRA1, but upregulate ZEB2 and SNAIL2. Parental A375 (A375P) and IPC-298 MM
cells were treated with indicated inhibitors for 24 hr. Protein expression was analyzed by immunoblotting.
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EMT-TFs (n = 89). The results showed low phospho-ERK levels
in nevi (Figure S2) and elevated expression in cancerous tissues,
primary MM (Figure 3A) and metastases (Figures S2B and S2C).
Importantly, phospho-ERK immunopositivity in MM samples
significantly correlated with elevated ZEB1 and low ZEB2 (Fig-
ures 3A and 3B) and represented a prognostic factor for poor
survival in MM patients (Figure 3C; Table S1). Therefore, IHC
analyses supported the in vitro data and indicated that MEK-
ERK pathway regulates EMT-TF reprogramming.
FRA1 Links BRAF Pathway with the Regulatory EMT-TF
Network
Zeb2/ mouse embryos express considerably more ZEB1 in
paraxial mesoderm and in neural folds than their wild-type coun-
terparts suggesting that Zeb1 is ZEB2-regulated (Miyoshi et al.,
2006). Likewise, in carcinoma cells, hierarchical reciprocal regu-
lation of EMT-TFs has been reported (Taube et al., 2010; Hugo
et al., 2011). These data indicate that regulatory interplay
between EMT-TFs may exist also in MM. To address this, we
assessed the kinetics of EMT-TF expression in response to
MEK inhibition in MM cells. Regulation of all four EMT-TFs was
transcriptional, and, importantly, upregulation of SNAI2 and
ZEB2 was rapid and apparently preceded repression of ZEB1
and TWIST1 (Figure 4A). These data suggested a hierarchy
between different EMT-TFs may exist. Indeed, we noted that in
some backgrounds depletion of certain individual EMT-TFs
affected the expression of the others; i.e., knock-down of
ZEB1 resulted in enhanced expression of ZEB2 in RPMI-7951Ccells (Figure 4B), and depletion of SNAI2 upregulated ZEB1 in
A375P and A375M cells (see Figure S6A). Knock-down of
ZEB2 activated ZEB1 in several MM cell lines including WM-
266-4, RPMI-7951, A375P, and A375M (Figures 4B, 4C, and
S6A). Moreover, ZEB2 depletion attenuated downregulation of
ZEB1 by U0126 (Figure 4C). Taken together with our observa-
tions that ZEB2 is replaced with ZEB1 in melanoma samples
(Figures 1 and S1), these data suggest that ZEB2 acts upstream
of ZEB1 in MEK-EMT-TF pathway.
We next aimed at identifying a molecular link between MEK
pathway and EMT-TF network. A double-negative feedback
loop involving miR-200 family members and ZEB transcription
factors regulates carcinoma cell plasticity. Enhanced expression
of the miR-200 family prevails in epithelial cells where it targets
ZEB1 and ZEB2, allowing expression of epithelial markers. In
mesenchymal cells, an autocrine TGF-b signaling prevents
expression of miR-200 and epithelial markers through upregula-
tion of ZEB factors (Brabletz and Brabletz, 2010). Our data
indicate that ZEB1 and ZEB2 genes are not coregulated in
MM, suggesting that the involvement of miR-200 is unlikely.
Indeed, miR-200 expression level in melanoma cells was much
lower than that in epithelial carcinoma cell lines (Figure 5A). In
line with these data, adjunction of miR-200-targeted 30UTR
sequences of ZEB1 or ZEB2 to a luciferase reporter impacted
on its activity in epithelial, but not in mesenchymal carcinoma
or MM cells (Figure S3A).
Given that EMT-TF regulation is transcriptional (Figure 4A),
we next evaluated the putative role of FRA1, an AP-1 family
member that was required for ZEB1/2 induction in responseancer Cell 24, 466–480, October 14, 2013 ª2013 Elsevier Inc. 469
Figure 3. EMT-TF Reprogramming Correlates with ERK Activation
(A) An example illustrating coexpression of phospho-ERK (p-ERK1/2) with ZEB1 and TWIST1 in primary melanoma. T, tumor; IL, infiltrating lymphocytes;
S, stroma.
(B) Expression of ZEB2 and ZEB1 correlates with phospho-ERK (p-ERK1/2) in malignant melanomas. Samples (n = 89) were separated in three groups according
to the IHC staining for ZEB proteins (H-score) as indicated, and compared with the levels of phospho-ERK. Statistical significance of correlations was determined
using Kruskal-Wallis test.
(C) Kaplan-Meier survival analysis of patients with malignant melanoma (n = 64) according to the presence of phospho-ERK in deep areas. Phospho-ERK
expression is a highly significant prognostic factor for poor survival.
See also Figure S2.
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Figure 4. Hierarchical Regulation of EMT-
TF Network: ZEB2 Represses ZEB1 in
Melanoma Cell Lines
(A) Kinetics of EMT-TF expression was analyzed in
A375P and A375M cells treated with 10 mMU0126
and incubated for different time periods as
indicated. EMT-TF expression was analyzed by
quantitative PCR (qPCR) (left panels) or immuno-
blotting (right panels). The results of qPCR
analyses are shown as mean ± SD of triplicate
experiments.
(B and C) Melanoma cells were treated with siRNA
targeting ZEB1 or ZEB2, left untreated (B), or
treated with 10 mM U0126 or DMSO for 24 hr, as
indicated (C) and analyzed by immunoblotting.
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In melanocytes and MM cells, FRA1 expression is BRAF-induc-
ible and MEK-dependent (Figure 2), as in other cell types
(Casalino et al., 2003). We depleted FRA1 by shRNA in BRAF-
transformed melan-a and in A375P MM cells and found that in
both cases FRA1 knockdown largely mimicked the effect of
MEK inhibition in MM cell lines by upregulating SNAI2/ZEB2,
but downregulating TWIST1 and ZEB1 protein levels (Figure 5B).
Next, we aimed to address whether FRA1 has a direct role in
transcriptional regulation of EMT-TFs in A375P MM cells. As
ZEB1 and ZEB2 genes produce several different transcript
variants and utilize alternative promoters (Figure S3B), we
employed 50RACE to identify their transcriptional promoters
that are active in MM cells (Figure S3C). Using chromatin immu-
noprecipitation assay, we detected FRA1 in association with
DNA fragments containing a canonical AP-1 binding site local-
ized to the middle part of the ZEB2 transcriptional silencer
(Chng et al., 2010) (Figure S3D). Likewise, we identified in vivo
FRA1 binding to AP-1 response elements located upstream of
transcription start sites of ZEB1, SNAI2, and TWIST1 genes
(Figure S3D). This indicates that FRA1 can directly modulate
transcription of EMT-TF-encoding genes downstream of MEK-
ERK pathway.
Overall, these data demonstratemutual regulation of EMT-TFs
in MM cells, which resembles complex interactomes reported in
EMT models in carcinoma cells (Taube et al., 2010; Hugo et al.,Cancer Cell 24, 466–480,2011). Moreover, we characterize a
pathway, which operates in melanoma
cells and couples BRAF and NRAS
mutations to the EMT-TF network. This
pathway is independent of the members
of miR-200 family and involves FRA1.
EMT-TF Switch Is a Determinant of
BRAF-Induced Transformation
Activation of BRAF or NRAS pathway is a
melanoma-initiating event. Therefore,
after establishing a link between this
pathway and EMT-TF expression, we
focused on the role of EMT-TF reprog-
ramming in BRAF-induced transforma-
tion. We uncoupled EMT-TF regulation
from BRAF mutant in melan-a cells eitherby ectopic expression of each of four EMT-TFs, or by shRNA-
mediated depletion of Zeb1 or Twist1 and examined the
transforming activity of BRAF mutant in these conditions. All
conditions impacted neither ERK activation nor cell proliferation
(data not shown). However, ectopic expression of SNAIL2 or
ZEB2, as well as depletion of ZEB1 or TWIST1 reproducibly
reduced the oncogenic potential of BRAF as evidenced by the
decreased number of colonies formed on soft agar (Figure 6A).
In contrast, exogenous ZEB1 or TWIST1 facilitated BRAF-driven
transformation of melan-a cells (Figure 6B). In line with these
data, in vivo experiments demonstrated that uncoupling BRAF
activation from EMT-TF reprogramming either inhibited or
delayed tumor development when cells were xenografted in
immunocompromised mice (Figure 6C). Data indicate that
although SNAIL2 and ZEB2 display tumor suppressor proper-
ties, TWIST1 and ZEB1 cooperate with BRAF in melanocyte
transformation.
Consistent with the role of FRA1 in orchestrating the EMT-TF
switch, its depletion in melan-a/DBRAF-ER cells reduced colony
formation, an effect that could be partially rescued by ectopic
expression of ZEB1 or TWIST1 (Figure 6D). To corroborate these
results we assessed the effect of ZEB2 and SNAIL2 on tumorige-
nicity of established MM cell lines. In agreement with the data
obtained in melan-a cells, simultaneous ectopic expression of
ZEB2 and SNAIL2 reduced colony formation potential and in vivo
tumorigenicity of both A375P and A375M cell lines (Figure S4).October 14, 2013 ª2013 Elsevier Inc. 471
Figure 5. The Switch in EMT-TFs Is miR-200-Independent, but
FRA1-Dependent in Melanoma Cells
(A) qPCR analyses of the expression of miR-200 family members in melanoma
(A375P and A375M), mesenchymal carcinoma (MDA-MB-231) or epithelial
carcinoma (RT112 and MDA-MB-468) cell lines. Data show mean ± SD of a
triplicate experiment.
(B) EMT-TF reprogramming is FRA1-dependent in BRAF-transformed mela-
nocytes and MM cell lines. Tamoxifen (4-OHT)-treated melan-a/DBRAF-ER
cells or A375P cells were either infected with a virus expressing shRNA
targeting FRA1, or mock infected. Protein expression was analyzed by
immunoblotting.
See also Figure S3.
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melanocyte transformation, but also have a tumor-suppressive
role in established melanoma cell lines.
EMT-TF Switch Affects Melanocyte Differentiation
Program
To explore a mechanism by which EMT-TF reprogramming con-
tributes to BRAF-induced transformation we performed gene
expression profiling of melan-a-derived cell lines expressing
active DBRAF-ER alone or in combination with ectopic SNAIL2,
ZEB2, TWIST1, or ZEB1. Clustering of the individual EMT-TF
gene expression profiles based on their similarity to each other
has revealed that ZEB1/TWIST1 and ZEB2/SNAIL2 generated472 Cancer Cell 24, 466–480, October 14, 2013 ª2013 Elsevier Inc.two pairs of dissimilar gene expression signatures (Figure 7A).
Melan-a transformation is associated with the downregulation
ofMitf and the subsequent inhibition of its target genes, including
tyrosinase, an enzyme-controlling melanin production (Well-
brock and Marais, 2005). Beyond its role in cell transformation,
subtle regulation of MITF expression is believed to determine
the differentiated/proliferative/invasive phenotypic switches
occurring in melanomagenesis (Hoek and Goding, 2010). As
expected, BRAF activation was associatedwith the downregula-
tion of Mitf expression (Figure 2A) and the repression of genes
regulating melanocyte differentiation downstream of MITF
(e.g., Tyr, Si, Mreg, Tyrp1, Trpm1, Slc45a2, Dct, Gpr143).
Enforced expression of SNAIL2 or ZEB2 restored Mitf and
MITF-target gene expression supporting the assumption that
these two EMT-TFs play a role in MITF-driven melanocyte differ-
entiation program. Conversely, ZEB1 and TWIST1 cooperated
with the BRAF oncoprotein in downregulatingMitf and other dif-
ferentiation markers (Figures 7A, S5A, and S5B). Consistent with
these data, rare soft agar colonies and xenografted tumors
generated frommelan-a/DBRAF-ER cells ectopically expressing
SNAIL2/ZEB2 or depleted of Zeb1/Twist1 were more pigmented
than those obtained with the parental cell line (see Figures 6A
and 6C). In agreement with the data generated in melan-a cells,
siRNA-mediated knockdown of SNAI2 or ZEB2 reduced MITF
protein levels in A375 and WM-266-4 melanoma cell lines
(Figure 7B). Furthermore, ectopic expression of ZEB1 in ZEB1-
negative melanoma cells (SK-MEL-5 and UACC-257) produced
a similar effect (Figure 7B). Thus, the repertoire of EMT-TFs in
melanoma cells regulates the level of MITF, and EMT-TF reprog-
ramming couples the activation of BRAF-FRA1 and NRAS-
FRA1 oncogenic pathways to dedifferentiation and malignant
transformation.
The Switch in EMT-TFs Is Associated with the Gain
in Invasive Properties and Loss of E-Cadherin
Gene expression analysis of melan-a-derived cells additionally
demonstrated that TGF-b-regulated genes (Bgn, Col5A1,
Fbn1, IL6, Lox, Tagln, Thbs1) (Hoek et al., 2006) and invasion-
associated genes (Mmp1a, Mmp3, Mmp13, Sparc) were
repressed in ZEB2/SNAIL2 group, but activated by TWIST1
and ZEB1 in combination with the BRAF mutant (Figures 7A,
S5C, and S5D). Consistent with these data, ectopic expression
of TWIST1 or ZEB1 activated, whereas ZEB2 or SNAIL2
repressed, matrigel invasion of melan-a/DBRAF-ER (Figure 8A).
Furthermore, although combined knockdown of ZEB1 and
TWIST1 in A375P and A375MMMcells decreased their invasive-
ness, depletion of SNAI2 and ZEB2 had no effect (Figure 8B).
Overall, these data point to a role of EMT-TF reprogramming in
control of MM cell invasion.
E-cadherin, a prototypical target of SNAIL, TWIST, and ZEB
family members, is often downregulated at the invasive front in
carcinomas as a result of EMT (Thiery et al., 2009; Brabletz
and Brabletz, 2010). Loss of membranous E-cadherin has
been documented also in vertical growth-phase melanomas at
deep sites in the dermis and in metastatic nodules predomi-
nantly in medullar parts (Sanders et al., 1999; Andersen et al.,
2004; Alexaki et al., 2010), i.e., in the areas where we identified
the EMT-TF switch. To establish a link between EMT-TF reprog-
ramming and loss of E-cadherin in melanoma, we assessed the
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in A375P and A375M melanoma cell lines. We found that,
among the EMT-inducers, ZEB1 was the only protein required
for the repression of the CDH1 gene in this cellular context
(Figure S6A). Consistent with these data, ZEB1, but not ZEB2
depletion-activated wild-type CDH1 gene promoter, whereas a
reporter driven by the promoter with mutagenized E-boxes
was insensitive to ZEB1 knockdown (Figure S6B). To sub-
stantiate these findings, we transiently expressed ZEB1 in
UACC-257 cells expressing E-cadherin, SNAIL2, and ZEB2
(Figure S6C) and observed inhibition of E-cadherin expression
in cells positive for ZEB1 (Figure S6D). In agreement with the
results of these experiments, no coexpression of E-cadherin
and ZEB1 was observed in a panel of melanoma cell lines
(Figure S6E).
Next, we assessed whether the expression of E-cadherin and
ZEB1 correlated in tumor samples. Given that loss of E-cadherin
has been reported in nodal metastases, we analyzed a cohort of
ten matched pairs of primary tumors and corresponding metas-
tases by IHC. E-cadherin immunoreactivity revealed a homoge-
neous staining in superficial areas of metastatic primary
melanomas and reduced level in deeper parts in some speci-
mens. Likewise, we observed a gradient of stronger cortical
staining for E-cadherin compared to the medullary sites in nodal
metastases, where in some areas E-cadherin was entirely lost.
Out of ten primary tumors with strong membrane-bound
E-cadherin immunoreactivity, eight showed reduced expression
in the corresponding metastases. ZEB1 was detected in 20% of
primary melanomas (deep areas) and in 40% of paired metasta-
ses (medullary metastatic deposits). Strikingly, ZEB1-positive
tumor areas showed lack of E-cadherin expression in all cases
(Figure 8C). This mutually exclusive pattern of ZEB1 and
E-cadherin expression strongly indicates a critical role of ZEB1
in EMT inmelanocytic lesions. Expression of ZEB2 was detected
in superficial areas of all primary melanomas and in 60% of cor-
responding metastases. ZEB1-positive tumor cells with absent
E-cadherin showed negative ZEB2 protein expression, but in
ZEB1-negative melanomas E-cadherin and ZEB2 were coex-
pressed (Figure 8C). In agreement with these data, downregula-
tion of E-cadherinwas concomitantwith EMT-TF reprogramming
in BRAFV600E-transduced primary human melanocytes (see Fig-
ure 2A). Taken together, our data show that in addition to its role
in cell transformation, EMT-TF reprogramming contributes to
loss of E-cadherin and activation of cell invasion in advanced
melanoma.
DISCUSSION
In epithelial backgrounds, EMT-TFs cooperate with mitogenic
oncoproteins in malignant transformation, tumor progression,
and metastatic dissemination (Ansieau et al., 2008; Thiery
et al., 2009; Rhim et al., 2012). Here, we demonstrate that in a
neural crest-derived malignancy, MM, the cross-talk between
EMT-TFs and oncogenic pathways has different configuration.
We show that normal melanocytes express two EMT-TFs,
SNAIL2 and ZEB2, but MM-driving ERK-activating oncogenic
pathways induce EMT-TF reprogramming, which involves
downregulation of SNAI2 and ZEB2 and upregulation of TWIST1
and ZEB1.CIn vitro, we detected EMT-TF reprogramming in untrans-
formed melanocytes in response to the BRAF activation. In
melanoma cell lines, MEK inhibition downregulated ZEB1 and
TWIST1, but upregulated ZEB2 and SNAI2 indicating that
continual MEK-ERK signaling is required to maintain the
reconfigured pattern of EMT-TF expression. By the analyses of
EMT-TF expression in melanoma samples, we detected EMT-
TF switch at late stages of MM progression in deep sites of
primary tumors and in medullary metastatic deposits in lymph
nodes. High expression of ZEB1 and decreased levels of ZEB2
significantly correlated with high phospho-ERK expression.
Remarkably, EMT-TF reprogramming and phospho-ERK immu-
nopositivity represented poor prognostic factors in melanoma
patients.
MEK-ERK pathway activation is the central event driving the
development of MM. Given high frequencies of mutually exclu-
sive MEK-ERK-activating mutations in BRAF (61%), NRAS
(20%) (Hodis et al., 2012), and a G protein-coupled receptor
gene GRM3 (16.3%) (Prickett et al., 2011), this pathway seems
to be activated in most melanocytic lesions including benign
nevi. However, there is a documented discrepancy between
mutational status of the pathway and phospho-ERK immuno-
positivity, with MAPK activity being much higher in MM than in
common acquired nevi (Saldanha et al., 2004; Uribe et al.,
2006; Venesio et al., 2008; Yazdi et al., 2010). This is likely to
be caused by the activation of different BRAF- or NRAS-depen-
dent negative feedback loops, such as IGFBP7 or an MEK-
inducible dual specificity phosphatases (DUSPs), which repress
the MEK-ERK pathway (Wajapeyee et al., 2008; Li et al., 2012;
Martin et al., 2012). Diverse mechanisms such as amplification
of mutant BRAF or NRAS alleles, acquired mutations in genes
encoding MEK1/2 or activation of EGFR signaling may bypass
suppression of MEK-ERK activity at later stages of MM (Udart
et al., 2001; Nikolaev et al., 2012). Our data indicate that EMT-
TF composition is dependent on activating mutations in BRAF
orNRAS oncogenes, but dynamically regulated thereafter during
MM progression mirroring the phospho-ERK expression pattern
(Figure 8D).
We also addressed molecular mechanisms linking MEK-ERK
pathway with EMT-TF reprogramming. In epithelial cells under-
going EMT, EMT-TFs are upregulated in hierarchical manner.
In some EMT models, SNAIL1, SNAIL2, and TWIST1 upregulate
ZEB1 and ZEB2 (Taube et al., 2010; Hugo et al., 2011; Dave
et al., 2011). In other systems, TWIST1 is upstream of SNAIL
family members activating SNAI2 and SNAI1 (Casas et al.,
2011). The interaction between EMT-TFs is complex also in
MM, where we demonstrate their mutual repression. We pro-
pose that reciprocal regulation of ZEB proteins in MM mediates
dynamic EMT-TF switches in course of melanoma progression
(Figure 8D). A regulatory feedback loop involving miR-200 family
members and TGF-b is a keymechanism that controls ZEB1 and
ZEB2 mRNA levels in carcinoma cells (Brabletz and Brabletz,
2010; Hill et al., 2013). However, in MM cells, miR-200 are pre-
sent at very low levels and not functional. We believe that lack
of miR-200 expression (possibly as a result of epigenetic
silencing) is in large responsible for the differences in the config-
urations of EMT-TF networks in MM and epithelial cells. We
show that the reorganization of the EMT-TF network in MM is
dependent at least in part on FRA1, one of the key effectors ofancer Cell 24, 466–480, October 14, 2013 ª2013 Elsevier Inc. 473
Figure 6. EMT-TF Switch Cooperates with BRAF in Malignant Transformation
(A) EMT-TF expression was modulated by infecting melan-a/DBRAF-ER cells with viral vectors expressing either SNAIL2 or ZEB2. In parallel experiments, Zeb1
or Twist1 expression was reduced by shRNA. The BRAF kinase has been activated with 4-OHT 2 weeks before plating. EMT-TF expression was assessed by
immunoblotting or qPCR as indicated (upper panels). Colony formation of 4-OHT-treated cells was analyzed, and the results of triplicate experiments (±SD) are
shown (lower panels).
(B) Melan-a/DBRAF-ER cells were infected with vectors harboring ZEB1 or TWIST1. The BRAF kinase has been activated with 4-OHT immediately before plating.
Expression of ZEB1 and TWIST1was analyzed by immunoblotting (left panels). Colony formation of 4-OHT-treated cells was analyzed, and the results of triplicate
experiments (±SD) are shown (right panels).
(legend continued on next page)
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EMT-TFs and Melanomagenesisthe RAS-MEK pathway (Vial et al., 2003). The crosstalk between
FRA1 and EMT-TFs appears to be complex and implies both
transcriptional and posttranslational mechanisms (data not
shown). However, FRA1 is associated with regulatory elements
within EMT-TFs genes-containing chromatin, and, therefore, it
has a potential to directly regulate EMT-TF expression.
We elucidated the functional outcome of EMT-TF reprogram-
ming in MM cells. EMT-TF network plays a more complex role
in MM than in epithelial backgrounds, with different EMT-TFs
having antagonistic functions. Specifically, although ZEB1 and
TWIST1 contribute to the malignant transformation, SNAIL2 and
ZEB2 act as oncosuppressive proteins. Recently, ZEB2 mRNA
was shown to suppress MM growth by enhancing PTEN expres-
sion in microRNA-dependent manner (Karreth et al., 2011). How-
ever, we did not observe any changes in PTEN expression levels
uponZEB2downregulation in eithermelan-a orA375Mcells (data
not shown). This implies that different mechanisms may underlie
oncosuppressive properties of ZEB2, and our data indicate that
antagonistic functions of EMT-TFs in MM correlate with their
opposing effects on MITF expression and function.
There are several lines of genetic evidence supporting the link
between SNAIL2 and ZEB2 to MITF and melanocyte differentia-
tion (Sa´nchez-Martı´n et al., 2002; Van de Putte et al., 2007; Liu
et al., 2009). In agreement with our findings, a recent study
demonstrated coexpression ofMITF and SNAIL2 inMM samples
(Shirley et al., 2012). A mechanism by which EMT-TFs regulate
MITF transcription remains undefined. We failed to detect any
effects of EMT-TFs onMITF promoter activity in reporter assays
(data not shown), suggesting an indirect effect similar to that
described for ATF2 (Shah et al., 2010). The role of MITF is not
limited to melanoma initiation, and currently its function is being
intensively discussed in the context of the mechanisms underly-
ing cell plasticity in MM (Cheli et al., 2010, 2011; Bell and Levy,
2011; Bertolotto et al., 2011). According to the phenotypic plas-
ticity model, the highest MITF expression maintains differenti-
ated status of cell-cycle arrested melanocytes. Reduced MITF
expression results in the transition to proliferative stage, whereas
further decrease in the MITF level generates invasive and slow-
proliferating cells with tumor-initiating properties (Hoek and
Goding, 2010). Our data suggest that EMT-TF network operates
upstream of MITF to control cell plasticity during melanomagen-
esis. Indeed, ZEB1 and TWIST1 induce TGF-b- and invasion-
associated gene signatures in concert with downregulating
MITF. In line with these findings, ZEB1 and TWIST1 stimulate
cell invasion; and E-cadherin loss, an attribute of aggressive
melanoma, is associated with elevated ZEB1.
Of note, nodal metastatic deposits recapitulated the same
EMT-TF and phospho-ERK expression gradients that we
observed in primary tumors. This may indicate that late-stage
MM cells retain the capability to reconstitute ‘‘differentiation(C)Melan-a/DBRAF-ER cells with the reduced or increased expression of individua
the appearance of tumors in each group of mice (left panels). Photographs illustra
especially, ZEB2 (right panels).
(D) FRA1 contributes to the oncogenic potential of BRAF. BRAF signaling was in
expressing or not exogenous ZEB1 or TWIST1. As positive control, we used 4-O
expression of ZEB1 and TWIST1 was confirmed by immunoblotting (left panels). O
of triplicate experiments (right panels).
See also Figure S4.
Cpattern’’ of EMT-TF expression (ZEB2high/SNAIL2high/ZEB1low/
TWIST1low), and MEK-ERK-dependent EMT-TF switches deter-
mine tumor cell plasticity during metastatic process via the
regulation of MITF expression. Alternatively, similar EMT-TF
expression patterns in primary and secondary tumors imply
that cancer cells may populate lymph nodes prior the feedback
mechanisms suppressing MEK-ERK signaling are activated.
Then, primary melanomas and lymph node metastases evolve
separately, but pass through similar cycles of EMT-TF reprog-
ramming. This explanation is within the framework of a theory
suggesting parallel progression of epithelial tumors and metas-
tases (Hu¨semann et al., 2008; Ansieau et al., 2008; Stoecklein
et al., 2008; Rhim et al., 2012). ZEB1high/TWIST1high MM cells
residing in medullar parts of lymph nodes may represent the
source for secondary wave of metastatic dissemination. In line
with this suggestion, medullary invasion is predictive of distant
metastases and poor survival in patients with MM (Scolyer
et al., 2008). On the other hand, our finding that SNAIL2 and
ZEB2 are highly expressed in cortical areas of lymph node
metastases is in agreement with a previous study linking SNAIL2
with high metastatic propensity of MM (Gupta et al., 2005).
EMT in epithelial tumors is a reversible process, and metasta-
tic carcinoma cells undergo MET in order to colonize distant
organs (Korpal et al., 2011; Tsai et al., 2012; Ocan˜a et al.,
2012). It is plausible to speculate that the scenario is similar in
MM: melanoma cells cycle between differentiated (ZEB2high/
SNAIL2high/MITFhigh/E-cadherinhigh) and oncogenic (ZEB1high/
TWIST1high/MITFlow/E-cadherin low) states to accomplish meta-
static process.
Recent clinical trials in patients with BRAF mutant melanoma
have shown that the acquired resistance to BRAF-selective
inhibitors is an important clinical challenge. In many cases, the
mechanism of the resistance was based on the restoration of
MEK activity (Emery et al., 2009; Villanueva et al., 2010). There-
fore, targeting EMT-TF network downstream of MEK represents
an attractive strategy for treatment ofMM. Given that FRA1 plays
an important role in EMT-TF reprogramming and is required for
melanocyte transformation by BRAF, molecular pathways regu-
lating FRA1 activity in MM appear as appealing targets for future
therapies.
EXPERIMENTAL PROCEDURES
All detailed information on experimental procedures and reagents is provided
in the Supplemental Experimental Procedures.
Human Samples and IHC
Melanocytic tissues were obtained from the consenting patients through
the Histopathology and Dermatology Departments, University Hospitals
of Leicester. Leicestershire Ethics Committee approval was obtained for
the tissue analysis (‘‘Molecular pathology of malignant melanoma’’ RECl EMT-TFswere grafted in immunocompromisedmice (n = 7). The graph shows
te high pigmentation of tumors with reduced TWIST1 or increased SNAIL2 and,
duced by 4OH-T treatment in melan-a/DBRAF-ER cells depleted of FRA1 and
HT-treated melan-a/DBRAF-ER cells infected with the control vector. Ectopic
ncogenicity was assessed in soft agar colony assay. The data are means ± SD
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Figure 7. EMT-TF Switch Affects Gene Expression Programs
(A) Genes differentially regulated by ZEB1/TWIST1 and ZEB2/SNAIL2 in melan-a/DBRAF-ER cells. Melan-a/DBRAF-ER cells were infected with either SNAIL2,
ZEB2, ZEB1, or TWIST1 retroviral expression vectors, treated with 4-OHT for 1 week, and processed for gene expression profiling. Fold changes are relative to
control melan-a/DBRAF-ER cells maintained in the absence of 4-OHT.
(B) The effects of EMT-TFs on MITF expression in MM cell lines. Melanoma cell lines were depleted of EMT-TFs by siRNAs (top panel), or ZEB1 was ectopically
expressed in ZEB1-negative cell lines SK-MEL-5 and UACC-257 (bottom panel). EMT-TF expression and the expression of MITF was analyzed by immuno-
blotting.
See also Figure S5.
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Figure 8. The EMT-TF Switch Is Associated with Increased Invasion and Loss of E-Cadherin
(A) Assessment of invasive potential of melan-a-/DBRAF-ER-derived cells in matrigel-coated BD transwells. Melan-a/DBRAF-ER cells were infected with either
SNAIL2, ZEB2, ZEB1, or TWIST1 retroviral expression vectors and treated with 4-OHT for 1 week. Fold changes in invasion relative to MOCK-infected melan-
a/DBRAF-ER cells in the presence of 4-OHT are shown. Results are shown as the mean ± SD of triplicate experiments.
(B) Simultaneous knockdown of TWIST1 and ZEB1, but not of SNAI2 and ZEB2, reduces invasion of A375P or A375M cells into matrigel. The invasion was
normalized to that of the cells transfected with control siRNA. Bars represent the mean ± SD of three independent experiments.
(C) Examples of IHC analyses demonstrating an in vivo correlation between ZEB1, ZEB2, and E-cadherin expression in primary melanoma (left panels) and
matched metastases (right panels). T, tumor; S, stroma; E, epidermis; LV, lymphatic vessel. ZEB1-positive cells observed in stromal areas are either invading
tumor cells, which underwent EMT-like reprogramming, or stromal components. These cells are marked with red arrows. Black arrows designate melanocytes
located in the epidermis.
(D) A hypothetical scheme illustratingmodulation of MAPK activity and EMT-TF reprogramming in the time course of tumor progression. Initial activation of MAPK
is caused by gain of function MM-driving mutations (BRAFV600E, NRASQ61L, etc.) MAPK activity is suppressed in nevi and in radial growth-phase melanoma
through negative feedback loops. The pathway is reactivated in advanced cancer via bypass mechanisms. An early EMT-TF switch is immediately induced by
oncogenic mutation, contributes to the neoplastic transformation, and is possibly involved in early dissemination. A late EMT-TF reprogramming is dependent on
continual MAPK signaling and leads to loss of E-cadherin and enhanced cell invasion. We hypothesize that the suppression of MAPK activity in nevi or horizontal-
phase melanoma causes EMT-TF reversion (suppression of ZEB1 and TWIST1 and reactivation of ZEB2 and SNAI2).
See also Figure S6.
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EMT-TFs and MelanomagenesisRef6791). Histological sections and formalin-fixed paraffin embedded tissue
blocks were retrieved from the archive. The primary tumors (n = 142)
were from the lower extremities (21.4%), the trunk (39.8%), the upper
extremities (17.3%), the head and neck (16.3%), and acral (4.1%). Of the
51 metastases, 76% were in lymph nodes, and the remaining metastases
were in skin or subcutaneous tissue. In addition, 26 common acquired nevi
were analyzed. Demographic information on the MM cases included age at
primary excision, gender, time to last follow-up visit/clinical metastasis.
Stage was determined from the Breslow thickness and ulceration of the
primary tumor.
Mouse Injection
Single cell suspensions ofmelan-a derivatives or A375MMcell lines (1–23 106
cells) in PBS/Matrigel (BD Biosciences) (1/1) were injected subcutaneously in
the flank of 8-week-old female athymic Swiss nude mice (Charles River
Laboratories). Tumor incidence and growth was monitored during different
time periods postinjection. Tumors grew up to 1.5 cm in diameter, at which
point animals were euthanized. Each tumor was dissected, fixed in formalin,
and processed for histopathology examination.
Mice were housed and bred in a specific pathogen-free animal facility
‘‘AniCan’’ at the CRCL, Lyon, France. The experiments were performed in
accordance with the animal care guidelines of the European Union and French
laws and were validated by the local Animal Ethic Evaluation Committee
(CECCAPP).
Statistics
Expression gradients within and between the lesions were analyzed by
Wilcoxon matched pairs test and Jonckheere-Terpstra trend test, respec-
tively. Unpaired data were compared by the Mann-Whitney U test or
Kruskal-Wallis one-way ANOVA. Paired data were analyzed by the Page
L test (Unistat Statistical Package, version 5.0, Unistat) and interrelation-
ships were investigated by linear regression analysis (Stata software pack-
age, version 7.0, Stata). Metastasis was investigated by Kaplan-Meier
analysis (Unistat) of H-score, which were compared by the log rank
Mantel-Haenzel (Peto) test, and by univariate and multivariate Cox regression
(Stata).ACCESSION NUMBERS
The GEO database accession number for the results of microarray experi-
ments reported in this paper is 39030.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2013.08.018.
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